Clinical Trial Update: PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating PD-1 blockade combined with Apatinib in relapsed or refractory NK/T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nk T-cell Lymphoma

Drugs mentioned

• Apatinib (apatinib)
• PD-1 inhibitor

Snippet

Sponsor: Peking University | Conditions: NK/T-cell Lymphoma | Phase 2 | Status: UNKNOWN